Mink Therapeutics Investor Relations Material
Latest events
Q1 2025
Mink Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mink Therapeutics Inc
Access all reports
Mink Therapeutics Inc. is a biotechnology company that focuses on developing immunotherapy treatments. The company specializes in creating allogeneic, off-the-shelf therapies derived from invariant natural killer T (iNKT) cells. These therapies are designed to target cancer and other immune-related diseases. Mink Therapeutics’ approach aims to harness the natural immune response, offering potential treatments that enhance the body’s ability to fight diseases. The company is headquartered in New York, United States, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
INKT
Country
🇺🇸 United States